9.229
Bearbeitungen
Änderungen
Zur Navigation springen
Zur Suche springen
Die Seite wurde neu angelegt: „{{NYT en}} right|thumb| '''Organogenesis''' is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{REFweb |quo…“
{{NYT en}}
[[Image:Organogenesis_logo.jpg|right|thumb|]]
'''Organogenesis''' is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{REFweb
|quote=The corporate headquarters and manufacturing facility are located in Canton, Massachusetts.
|last=
|first=
|publisher=Organogenesis
|date=2010
|title=Headquarters
|url=http://www.organogenesis.com/about_us/headquarters.html
|accessdate=2011-03-06
}}</ref> They profit from [[Apligraf]], which is a synthetic skin created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb
|quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.
|last=
|first=
|publisher=Organogenesis
|date=2011
|title=Apligraf: How Is It Made?
|url=http://www.apligraf.com/professional/what_is_apligraf/how_is_it_made/
|accessdate=2011-03-06
}}</ref> Novartis Pharmaceuticals Corp. has global marketing rights to Apligraf.
== Call for increase of foreskin harvesting ==
{{Zitat
|Titel=We Must Be Able To Obtain Adequate Sources Of Supply
|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the HIV or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
|Autor=
|Quelle=Organogensis
|ref=<ref>[http://sec.edgar-online.com/organogenesis-inc/10-k-annual-report/2001/04/02/Section2.aspx Organogensis, 2001 Annual Report (Delaware: Organogenesis, 2001), p.8.]</ref>
}}
== Apligraph Oral ==
Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb
|last=
|first=
|date=2011-11-17
|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript
|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf
|publisher=
|accessdate=2011-12-20
}}</ref>
{{REF}}
[[Kategorie:Organisationen]]
[[Kategorie:Von CircLeaks]]
[[Kategorie:Von IntactWiki]]
[[en:{{FULLPAGENAME}}]]
[[Image:Organogenesis_logo.jpg|right|thumb|]]
'''Organogenesis''' is a corporation based in Canton, MA.<ref name='Organogenesis 2010'>{{REFweb
|quote=The corporate headquarters and manufacturing facility are located in Canton, Massachusetts.
|last=
|first=
|publisher=Organogenesis
|date=2010
|title=Headquarters
|url=http://www.organogenesis.com/about_us/headquarters.html
|accessdate=2011-03-06
}}</ref> They profit from [[Apligraf]], which is a synthetic skin created from harvested foreskins.<ref name='Organogenesis 2011'>{{REFweb
|quote=Human keratinocytes and fibroblasts are derived from neonatal foreskins.
|last=
|first=
|publisher=Organogenesis
|date=2011
|title=Apligraf: How Is It Made?
|url=http://www.apligraf.com/professional/what_is_apligraf/how_is_it_made/
|accessdate=2011-03-06
}}</ref> Novartis Pharmaceuticals Corp. has global marketing rights to Apligraf.
== Call for increase of foreskin harvesting ==
{{Zitat
|Titel=We Must Be Able To Obtain Adequate Sources Of Supply
|Text=We manufacture Apligraf for commercial sale, as well as for use in clinical trials, at our Canton, Massachusetts facility. Among the fundamental raw materials needed to manufacture Apligraf are keratinocyte and fibroblast cells. Because these cells are derived from donated infant foreskin, they may contain human-borne pathogens. We perform extensive testing of the cells for pathogens, including the HIV or "AIDS" virus. Our inability to obtain cells of adequate purity, or cells that are pathogen-free, would limit our ability to manufacture sufficient quantities of our products.
|Autor=
|Quelle=Organogensis
|ref=<ref>[http://sec.edgar-online.com/organogenesis-inc/10-k-annual-report/2001/04/02/Section2.aspx Organogensis, 2001 Annual Report (Delaware: Organogenesis, 2001), p.8.]</ref>
}}
== Apligraph Oral ==
Organogenesis is presently seeking [[FDA]] approval for Apligraph Oral, a foreskin-derived product for the "treatment of surgically treated gingival and alveolar mucosal surface defects in adults."<ref>{{REFweb
|last=
|first=
|date=2011-11-17
|title=November 17, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting: Transcript
|url=http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM284112.pdf
|publisher=
|accessdate=2011-12-20
}}</ref>
{{REF}}
[[Kategorie:Organisationen]]
[[Kategorie:Von CircLeaks]]
[[Kategorie:Von IntactWiki]]
[[en:{{FULLPAGENAME}}]]